ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma

Results of two phase III trials, presented at ASCO, on the addition of bevacizumab (Avastin) to standard therapy in newly diagnosed glioblastoma found that the drug added no benefit.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news